Get to know our clinical trials
Randomized, double-masked, comparative clinical trial to evaluate the efficacy, safety, and immunogenicity of ABP 938 8 mg compared with EYLEA® HD
THIS RESEARCH STUDY EVALUATES ABP 938 8 MG COMPARED WITH COMMERCIALLY AVAILABLE AFLIBERCEPT (EYLEA® HD). ITS AIM IS TO DETERMINE WHETHER THE EFFICACY (HOW WELL THE STUDY DRUG INJECTION WORKS), SAFETY, AND IMMUNOGENICITY (THE ABILITY TO TRIGGER A RESPONSE IN THE BODY TO THE STUDY DRUG INJECTION THROUGH THE DEVELOPMENT OF ANTIBODIES, A TYPE OF PROTEIN) OF ABP 938 8 MG ARE SIMILAR TO THOSE OF AFLIBERCEPT (EYLEA® HD) IN THE OVERALL STUDY POPULATION.
Technical Summary
- RANDOMIZED, DOUBLE-MASKED, COMPARATIVE CLINICAL STUDY TO EVALUATE THE EFFICACY, SAFETY, AND IMMUNOGENICITY OF ABP 938 8 MG COMPARED WITH EYLEA® HD (AFLIBERCEPT), ADMINISTERED BY INTRAVITREAL INJECTION IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
- Code EudraCT: 2025-523500-72
- Protocol number: 20250115
- Promoter: Amgen, S.A.
- Molecule/Drug: ABP 938
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.